Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Eisai's anticancer agent eribulin mesilate receives priority review status in Japan

June 23, 2010

StemEx receives FDA fast track designation

June 23, 2010

OncoGenex begins phase III custirsen sodium trial in metastatic prostate cancer

June 23, 2010

Cellceutix concludes preclinical studies of Kevetrin in multidrug-resistant cancer cells

June 23, 2010

TH-302/doxorubicin combination is safe in phase I/II trial in soft tissue sarcoma

June 23, 2010

Novel PDK1 inhibitors claimed by MSD for cancer therapy

June 23, 2010

Exelixis regains rights to XL-184

June 22, 2010

FDA advises on phase III palifosfamide trial in metastatic soft tissue sarcoma

June 22, 2010

PX-478 shows antitumor activity in phase I trial in advanced solid tumors

June 22, 2010

Phase I/II trial of new proapoptotic agent APR-246 advances

June 22, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 24, 2026.
Have brain-computer interfaces finally arrived?
BioWorld
More and more individuals now have chronically implanted brain-computer interface (BCI) systems in their heads. Devices that can record and stimulate neural...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 23, 2026
K2 nabs two Antengene bispecific TCEs in $2B license, option deal
BioWorld
MPM Bioimpact-spawned K2 Therapeutics Inc. inked a license deal plus option agreement, worth $980.5 million apiece, to gain ex-China rights to two of Antengene...
In the clinic for June 22, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Alkermes, Boehringer, Cambrian, F2G, Intrabio, Lexeo, Memo, Novocure,...